Private biotechs draw $2B in huge fundraising week: Venture Report

The short period between the holiday season and the start of the J.P. Morgan Healthcare Conference has once again proven to deliver a burst of venture fundings for biotechs, with at least seven companies drawing at least $100 million apiece, and the sector pulling in more than $2 billion in private capital.

The $305 million series F round for Parabilis Medicines Inc. lifted the start-up’s total venture funding to date above $800 million, with numerous crossovers joining or returning to its syndicate. With optimistic signs in the public markets, Parabilis could soon test NASDAQ’s appetite for an offering; Friday’s upsized deal and 24% first-day pop by Aktis Oncology Inc. (NASDAQ:AKTS) is surely a positive signal...